Study of AZD0516 as Monotherapy and in Combination in Participants with Metastatic Prostate Cancer

Trial Identifier: D9520C00001
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: October 2025
Primary Completion Date: January 2029
Study Completion Date: January 2029
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BR Barretos, BR, 14784-400
BR Porto Alegre, BR, 90035-001
BR Sao Paulo, BR, 01401-002
CN Changsha, CN, 410013
CN Chengdu, CN, 610041
CN Wuhan, CN, 430022
ES Barcelona, ES, 08035
ES Barcelona, ES, 08036
ES Barcelona, ES, 08041
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28027
ES Pamplona, ES, 31005
ES Santander, ES, 39008
ES Valencia, ES, 46009
FR Lyon, FR, 69008
FR Montpellier, FR, 34298
FR Saint Herblain, FR, 44805
FR SURESNES CEDEX, FR, 92151
FR Villejuif, FR, 94805
GB Cambridge, GB, CB2 0QQ
GB London, GB, EC1A 7BE
GB London, GB, SE1 9RT
GB Plymouth, GB, PL6 8DH
GB Sutton, GB, SM2 5PT
IT Milano, IT, 20141
IT Milano, IT, 20133
IT Milano, IT, 20132
IT Napoli, IT, 80131
IT Roma, IT, 00168
IT Rozzano, IT, 20089
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 277-8577
JP Koto-ku, JP, 135-8550
KR Seoul, KR, 03722
KR Seoul, KR, 5505
KR Seoul, KR, 03080
KR Seoul, KR, 06591
KR Seoul, KR, 06351
PL Koszalin, PL, 75-581
PL Piotrków Trybunalski, PL, 97-300
PL Przemysl, PL, 37-700
US, AR Fayetteville, AR, US, 72703
US, CA Los Angeles, CA, US, 90095
US, MA Boston, MA, US, 02114
US, MI Ann Arbor, MI, US, 48109
US, MI Detroit, MI, US, 48201
US, NY Buffalo, NY, US, 14263
US, NY New York, NY, US, 10065
US, RI Providence, RI, US, 02906
US, SC Myrtle Beach, SC, US, 29572
US, TX Houston, TX, US, 77030